Results 31 to 40 of about 463,157 (297)
Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1 [PDF]
JAMA Oncology, 2019 Therapies to inhibit programmed cell death 1 and its ligand (anti-PD-1/PD-L1) provide significant survival benefits in many cancers, but the efficacy of these treatments varies considerably across different cancer types. Identifying the underlying variables associated with this cancer type-specific response remains an important open research challenge ...
Joo Sang, Lee, Eytan, Ruppin
openaire +2 more sources
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
BMC Cancer, 2022 Background Mantle cell lymphoma (MCL) has remained incurable in most patients. The expression of PD-L1 as a prognostic and predictive marker has not been fully evaluated in MCL.
Fereshteh Ameli +3 more
doaj +1 more source
Molecules, 2022 New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex.
Shabnam Shaabani +12 more
doaj +1 more source
Chinese Journal of Lung Cancer, 2020 As a new method, immunotherapy which is targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) plays a more and more important role in the treatment of malignant tumors.
Tongji XIE, Shouzheng WANG, Puyuan XING
doaj +1 more source
Frontiers in Oncology, 2021 BackgroundProgrammed death 1/ligand 1 (PD-1/L1) inhibitors have acceptable antitumor activity in patients with platinum-resistant urothelial cancer (UC).
Zaishang Li +20 more
doaj +1 more source
Differential Requirement for CD70 and CD80/CD86 in Dendritic Cellmediated Activation of Tumor Tolerized CD8 T Cells [PDF]
, 2012 A major obstacle to efficacious T cell-based cancer immunotherapy is the tolerizing-tumor microenvironment that rapidly inactivates tumor-infiltrating lymphocytes.
Bai, Ailin +5 more
core +1 more source
Brain Sciences, 2022 Purpose: This study aims to investigate PD-1/PD-L1 expression patterns in paired primary and recurrent gliomas. Methods: From January 2008 to December 2014, 42 patients who underwent surgical resections of primary and recurrent gliomas were ...
Wei Yu +5 more
doaj +1 more source
Diversification of a protein kinase cascade: IME-2 is involved in nonself recognition and programmed cell death in Neurospora crassa. [PDF]
, 2012 Kinase cascades and the modification of proteins by phosphorylation are major mechanisms for cell signaling and communication, and evolution of these signaling pathways can contribute to new developmental or environmental response pathways.
Bueche, Joanna A +2 more
core +2 more sources
Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors of Small Cell Lung Cancer
Chinese Journal of Lung Cancer, 2020 Inhibitions of immune checkpoints, including programmed cell death 1-programmed cell death-ligand 1 (PD-1-PD-L1) axis, cytotoxic T lymphocyte associated antigen-4, are at the forefront of immunotherapy for small cell lung cancer.
Yaning YANG, Yan WANG
doaj +1 more source
Frontiers in Immunology, 2023 BackgroundMultiple clinical studies have indicated that the gut microbiota influences the effects of immune checkpoint blockade (ICB) therapy comprising PD-1/PD-L1 inhibitors, but the causal relationship is unclear.
Yu-Feng Huang +9 more
doaj +1 more source